Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 12/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 3/20 | 0.38 |
| ▸ | FLT4 | P35916 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180926 | 0.86 | FLT1 (0.46) | IMPDH2ALDH1A1FLT1FLT4KDR | |
| SCHEMBL2876223 | 0.85 | AOC3 (0.44) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6182372 | 0.84 | VCP (0.46) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6178869 | 0.83 | FLT1 (0.53) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6179167 | 0.83 | IMPDH2 (0.42) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6196840 | 0.82 | IMPDH2 (0.51) | IMPDH2 | |
| SCHEMBL6179818 | 0.81 | IMPDH2 (0.45) | IMPDH2 | |
| SCHEMBL6179950 | 0.80 | IMPDH2 (0.43) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6196662 | 0.80 | IMPDH2 (0.43) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6181196 | 0.79 | IMPDH2 (0.43) | IMPDH2MEN1RAB9AKMT2AFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448187-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1448187-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-08-25 | — | — | EP | claimed |
| US-6596747-B2 | For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| WO-2003047512-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | claimed |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | claimed |
| US-6596747-B2 | For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885MAPT 2853/4885ALDH1A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.